Results 141 to 150 of about 122,145 (339)
Beyond GLP‐1: The Cardiometabolic Potential of Dual GLP‐1/GIP Receptor Agonists
iNew Medicine, EarlyView.
Chao Xue
wiley +1 more source
Obesity, EarlyView.ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu +13 more
wiley +1 more source
Obesity, EarlyView.ABSTRACT The off‐label use of glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses ...
Fernanda Baeza Scagliusi +5 more
wiley +1 more source
Obesity, EarlyView.ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo +4 more
wiley +1 more source
Obesity, EarlyView.ABSTRACT Objective This study aimed to evaluate whether reduced‐frequency dosing of GLP1 receptor agonists maintains weight loss, body composition, and metabolic syndrome improvements following successful initial treatment with standard weekly therapy. Methods This retrospective case series included 30 adults who achieved weight plateau while on weekly
Michelle Wong +3 more
wiley +1 more source
Once-weekly glucagon-like peptide 1 receptor agonists.
JPMA. The Journal of the Pakistan Medical Association, 2015 The once-weekly glucagon-like peptide 1 receptor agonists (QW GLP1RA) represent a major advancement in diabetes pharmaco-therapeutics. This review describes the basic, clinical, and comparative pharmacology of this novel class of drugs. It highlights the clinical placement and posology of these drugs.
Sanjay, Kalra, Yashdeep, Gupta
openaire +1 more source
GLP‐1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?
The Laryngoscope, EarlyView.
Alina Zgardau +3 more
wiley +1 more source
Obesity, EarlyView.ABSTRACT Objective This study compared population characteristics and overall US prevalence of obesity over time using the BMI criteria and the 2025 Lancet Commission criteria (i.e., the Excess Adiposity criteria). Methods We analyzed data from 58,053 adults aged ≥ 20 years in the National Health and Nutrition Examination Survey from 1999 to 2023.
Jennifer H. Hwang, Neda Laiteerapong
wiley +1 more source
npj Systems Biology and ApplicationsGlucagon-like peptide-1 (GLP-1) is a hormone known for its critical functions in managing blood sugar and offering cardiovascular benefits. Our study focuses on Glucagon Like Peptide 1 Receptor (GLP1R) agonists that act beyond glycemic control in ...
Zofia Wicik +7 more
doaj +1 more source
Food Retention at Endoscopy Among Adults Using Glucagon-Like Peptide-1 Receptor Agonists
JAMA Network OpenThis cross-sectional study investigates the association between glucagon-like peptide-1 receptor agonists and food retention during esophagogastroduodenoscopy.
Jason Nasser +6 more
semanticscholar +1 more source